68 results
Page 2 of 4
6-K/A
EX-99.1
37hrg9xdk
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
4zu4yfm
14 Nov 22
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
7:59am
6-K
EX-99.3
q8tbfcgu8 qgmxjrjgk
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
b98eow6 5de1o4
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
ijre22
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
8fhx em5nl9g
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.3
0xxs7l7x13g8ghqu
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
8u0681fhm rpr93q
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
v0xoug
11 Jul 22
Immunocore announces dosing of first patient with ImmTAV® bispecific for HIV
4:05pm
6-K
EX-99.1
1cucp 78onsgrybs3
27 Jun 22
Current report (foreign)
4:05pm
6-K
EX-99.1
v1drgi2b jzw
8 Jun 22
KIMMTRAK is the first and only treatment approved in the UK, Australia, and Canada to treat patients with unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
pvmvv198845 i9sj
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.1
6t0b6urd 4xmikfwmj7e
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
ydnvur8
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
424B7
8ht3ladm445u7 ujk7i
5 May 22
Prospectus with selling stockholder info
12:00am
6-K
EX-99.1
oklr7mb qq
14 Apr 22
Current report (foreign)
4:11pm
F-3ASR
z0wq2ffe
4 Apr 22
Automatic shelf registration (foreign)
4:08pm
6-K
EX-99.1
byc8h6
4 Apr 22
European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
4:06pm
6-K
EX-99.1
uh9ndkgeil qx
3 Mar 22
Immunocore Reports Full Year 2021 Financial Results
7:01am